{"id":15426,"date":"2025-08-22T04:43:07","date_gmt":"2025-08-22T04:43:07","guid":{"rendered":"https:\/\/www.europesays.com\/ie\/15426\/"},"modified":"2025-08-22T04:43:07","modified_gmt":"2025-08-22T04:43:07","slug":"chinas-rise-in-biotech-to-potentially-lower-healthcare-costs-life-science-investor-says","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ie\/15426\/","title":{"rendered":"China\u2019s rise in biotech to potentially lower healthcare costs, life science investor says"},"content":{"rendered":"<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">China\u2019s rise in biotech innovation offers the world a potentially cheaper alternative to costly healthcare products from Western suppliers, but geopolitical tensions remain a major challenge for the country\u2019s globalisation efforts, according to a local investor in the sector.<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">\u201cWe can lower the cost of healthcare and benefit more people through technological innovation and efficiency improvement,\u201d Da Liu, managing director of CR-CP Life Science Fund, said in an interview with the Post earlier this week. \u201cChina\u2019s recent achievements in biotech show that it\u2019s possible.\u201d<\/p>\n<p datatype=\"p\" data-qa=\"Component-Component\" class=\"e8zc9q40 css-1c6uqr6 ec74h0k1\">The CR-CP Life Science Fund was launched in 2019 by the state-run China Resources Group and Thai conglomerate Charoen Pokphand Group, with US$170 million under management. Companies the fund has backed include Legend Biotech, which went public in New York in 2020, and Singapore-based Mirxes, which listed its shares in Hong Kong in May this year.<\/p>\n<p>Innovative drugs coming out of China\u2019s biotech firms have become increasingly popular licensing targets among multinational corporations (MNCs) in recent years, leading to what some are calling a <a target=\"_self\" class=\"e1yy41x40 ef9u0v01 css-1ankfgb ecgc78b0\" href=\"https:\/\/www.scmp.com\/tech\/tech-trends\/article\/3310642\/biotechs-deepseek-moment-hong-kong-investor-ori-sees-opportunity-china-new-fund?module=inline&amp;pgtype=article\" title=\"\" data-qa=\"BaseLink-renderAnchor-StyledAnchor\" rel=\"nofollow noopener\">\u201cDeepSeek moment\u201d<\/a> for the local industry.<img decoding=\"async\" alt=\"Da Liu, managing director of CR-CP Life Science Fund. Photo: Handout\" data-qa=\"BaseImage-handleRenderImage-StyledImage\" class=\"e1gf69pb2 css-6ikqhs e445x7d0\" loading=\"lazy\" src=\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2025\/08\/c9fa4825-a583-4d25-ae1e-ca29df912e26_8b7bd641.jpg\" title=\"Da Liu, managing director of CR-CP Life Science Fund. Photo: Handout\"\/>Da Liu, managing director of CR-CP Life Science Fund. Photo: HandoutMultinationals have turned their attention to Chinese biotech companies and assets because of their \u201ccost efficiencies, accelerated timelines and promising quality\u201d, <a target=\"_self\" class=\"e1yy41x40 ef9u0v01 css-1ankfgb ecgc78b0\" href=\"https:\/\/www.scmp.com\/business\/article\/3318179\/chinas-drug-prowess-show-global-event-drawing-industry-shoppers-jefferies?module=inline&amp;pgtype=article\" title=\"\" data-qa=\"BaseLink-renderAnchor-StyledAnchor\" rel=\"nofollow noopener\">US investment bank Jefferies said<\/a> in a report last month.<\/p>\n","protected":false},"excerpt":{"rendered":"China\u2019s rise in biotech innovation offers the world a potentially cheaper alternative to costly healthcare products from Western&hellip;\n","protected":false},"author":2,"featured_media":15427,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[275],"tags":[13994,381,13988,13990,13995,13985,18,135,475,474,4202,19,17,13992,13987,13993,13996,13986,13991,4434,13989],"class_list":{"0":"post-15426","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-charoen-pokphand-group","9":"tag-china","10":"tag-china-resources-group","11":"tag-cr-cp-life-science-fund","12":"tag-da-liu","13":"tag-deepseek-moment","14":"tag-eire","15":"tag-health","16":"tag-health-care","17":"tag-healthcare","18":"tag-hong-kong","19":"tag-ie","20":"tag-ireland","21":"tag-jefferies","22":"tag-legend-biotech","23":"tag-life-sciences-unicorns-from-a-china-investment-perspective","24":"tag-mirxes","25":"tag-mncs","26":"tag-pharmcube","27":"tag-southeast-asia","28":"tag-western"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=15426"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/15426\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/15427"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=15426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=15426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=15426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}